I was the first patient in the US that enrolled in the RucaPANC trial for targeted therapy in metastatic pancreatic cancer patients possessing a germline or somatic BCRA1, 2 or PALB2 mutation. I had a two week pause after finishing Folfirinox while it was still showing efficacy. I had a complete response to the PARP inhibitor Rubraca (Rucaparib) and now the longest patient in the world on this PARP inhibitor. I was in the trial from October 2014 until it was terminated in April 2016 and continued on the drug under compassionate need status. I am followed long term every six weeks and have been NED since at least 2016 and an 11.5 year survivor of metastatic disease to the liver of which there is no trace today.

The top two experts on BRCA in pancreatic cancer patients are Kim Reiss-Binder at the Abramson Cancer Center of the Hospital of the University of Pennsylvania (PennMedicine) and Eileen O’Reilly of MSKCC. I would contact those two for opinions in doing maintenance monotherapy with a PARP inhibitor such as Olaparib (Lynparza).